These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36226625)

  • 1. Association of the serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis.
    Li X; Bai J; Li S; Li M; Zeng X; Wang Q; Hu C
    Clin Exp Rheumatol; 2023 Mar; 41(2):230-237. PubMed ID: 36226625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients.
    Zeng X; Li S; Tang S; Li X; Zhang G; Li M; Zeng X; Hu C
    Front Immunol; 2021; 12():669137. PubMed ID: 34248947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
    Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
    J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
    Cordel N; Dechelotte B; Jouen F; Lamb JA; Chinoy H; New P; Vencovsky J; Mann H; Galindo-Feria AS; Dani L; Selva-O'Callaghan A; Werth VP; Ravishankar A; Landon-Cardinal O; Tressières B; Boyer O
    Rheumatology (Oxford); 2023 Apr; 62(4):1711-1715. PubMed ID: 36250907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
    Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
    Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
    Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
    Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
    Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
    Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
    Front Immunol; 2022; 13():879266. PubMed ID: 35603153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
    Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
    Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
    Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
    J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
    Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
    Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
    Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
    Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies.
    Ly NTM; Ma N; Ueda-Hayakawa I; Nguyen CTH; Anada R; Okamoto H; Fujimoto M
    J Dermatol Sci; 2021 Dec; 104(3):177-184. PubMed ID: 34772582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective screening of serum IgG glycosylation biomarker for primary Sjögren's syndrome using lectin microarray.
    Li S; Zeng X; Tang S; Li X; Zhang G; Li M; Zeng X; Hu C
    PeerJ; 2023; 11():e14853. PubMed ID: 36852221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
    Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
    J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
    Kotobuki Y; Tonomura K; Fujimoto M
    Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.